Published in Lancet on December 10, 2005
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Malaria: progress, perils, and prospects for eradication. J Clin Invest (2008) 6.54
Acquired immunity to malaria. Clin Microbiol Rev (2009) 6.24
Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med (2010) 5.71
A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A (2008) 3.56
A research agenda for malaria eradication: vaccines. PLoS Med (2011) 3.33
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis (2008) 2.77
Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci (2008) 2.39
TLR-based immune adjuvants. Vaccine (2010) 2.10
Advances and challenges in malaria vaccine development. J Clin Invest (2010) 2.03
Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis (2013) 2.00
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis (2015) 1.97
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
Malaria eradication and elimination: views on how to translate a vision into reality. BMC Med (2015) 1.86
Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med (2012) 1.83
A 10 year study of the cause of death in children under 15 years in Manhiça, Mozambique. BMC Public Health (2009) 1.76
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun (2007) 1.75
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A (2006) 1.74
Malaria in rural Mozambique. Part II: children admitted to hospital. Malar J (2008) 1.72
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A (2009) 1.72
Malaria in rural Mozambique. Part I: children attending the outpatient clinic. Malar J (2008) 1.68
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One (2009) 1.66
Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One (2009) 1.65
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials (2006) 1.65
Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One (2009) 1.64
Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev (2008) 1.64
Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ (2011) 1.62
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One (2008) 1.56
Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice. Vaccine (2010) 1.54
Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol (2008) 1.52
Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin (2010) 1.50
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials (2006) 1.47
Evidence for over-dispersion in the distribution of clinical malaria episodes in children. PLoS One (2008) 1.44
Immune mechanisms in malaria: new insights in vaccine development. Nat Med (2013) 1.40
Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J (2011) 1.38
What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One (2008) 1.38
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials (2006) 1.36
How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar J (2007) 1.35
Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis (2008) 1.32
World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J Immunol (2009) 1.32
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One (2009) 1.31
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun (2006) 1.30
Malaria parasite pre-erythrocytic stage infection: gliding and hiding. Cell Host Microbe (2008) 1.30
Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol (2009) 1.30
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J (2007) 1.29
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine (2007) 1.28
Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One (2009) 1.26
A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun (2006) 1.25
Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru. Malar J (2008) 1.23
Evaluation of a PfHRP2 and a pLDH-based rapid diagnostic test for the diagnosis of severe malaria in 2 populations of African children. Clin Infect Dis (2011) 1.23
A mathematical model of the impact of present and future malaria vaccines. Malar J (2013) 1.23
Malaria vaccines and their potential role in the elimination of malaria. Malar J (2008) 1.21
Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am J Trop Med Hyg (2007) 1.20
Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun (2007) 1.19
Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents (2013) 1.19
Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission. Infect Immun (2008) 1.17
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J (2011) 1.11
Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun (2009) 1.11
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malar J (2011) 1.11
Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa. BMC Med Ethics (2007) 1.08
Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines (2012) 1.07
Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One (2007) 1.06
WHO policy development processes for a new vaccine: case study of malaria vaccines. Malar J (2010) 1.06
Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J Clin Invest (2010) 1.05
Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D). PLoS One (2011) 1.04
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One (2011) 1.04
Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites. PLoS One (2009) 1.04
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin (2009) 1.01
Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun (2013) 1.00
The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial. PLoS One (2012) 0.99
RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites. Mol Cell Proteomics (2014) 0.99
Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One (2010) 0.99
Circulating Th1-Cell-type Tfh Cells that Exhibit Impaired B Cell Help Are Preferentially Activated during Acute Malaria in Children. Cell Rep (2015) 0.98
T-cell-inducing vaccines - what's the future. Immunology (2012) 0.95
Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data. BMC Med (2013) 0.94
Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One (2008) 0.93
Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine (2011) 0.92
Towards an effective malaria vaccine. Arch Dis Child (2007) 0.92
Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proc Biol Sci (2010) 0.92
Malaria drives T cells to exhaustion. Front Microbiol (2014) 0.90
MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy. PLoS One (2010) 0.89
Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun (2007) 0.89
A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One (2007) 0.89
Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria. Vaccine (2007) 0.89
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults. PLoS One (2015) 0.88
High-throughput molecular diagnosis of circumsporozoite variants VK210 and VK247 detects complex Plasmodium vivax infections in malaria endemic populations in Papua New Guinea. Infect Genet Evol (2010) 0.88
Advances and challenges in malaria vaccine development. Expert Rev Mol Med (2009) 0.86
Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS One (2011) 0.85
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses. Clin Vaccine Immunol (2008) 0.85
Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect Immun (2006) 0.85
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines (Basel) (2014) 0.84
Murine infection models for vaccine development: the malaria example. Hum Vaccin Immunother (2012) 0.84
Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection. Philos Trans A Math Phys Eng Sci (2008) 0.83
Antigens for pre-erythrocytic malaria vaccines: building on success. Parasite Immunol (2009) 0.83
Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet (2013) 14.06
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 9.24
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis (2009) 6.90
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet (2007) 4.83
Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med (2008) 4.35
Cause-specific mortality rates in sub-Saharan Africa and Bangladesh. Bull World Health Organ (2006) 4.12
Mass treatment with single-dose azithromycin for yaws. N Engl J Med (2015) 3.84
Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet (2005) 3.79
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis (2006) 3.17
The role of mobile phones in improving vaccination rates in travelers. Prev Med (2004) 2.95
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa. Nat Genet (2012) 2.86
Efficacy of single-dose antibiotic against early-onset pneumonia in comatose patients who are ventilated. Chest (2013) 2.85
Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J (2009) 2.83
Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. Lancet (2012) 2.81
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol (2003) 2.71
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urine. J Infect Dis (2009) 2.64
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis (2011) 2.54